Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 31 n°159

Posts Tagged ‘zai lab’

Novocure and Zai Lab to Host Investor Event

Posted by fidest press agency su venerdì, 9 novembre 2018

Novocure (NASDAQ: NVCR) announced today that it will host an investor event with Zai Lab on Nov. 14, 2018, in Shanghai, China. William Doyle, Novocure’s Executive Chairman, Dr. Samantha Du, Zai Lab’s CEO, and Tao Fu, Zai Lab’s President and Chief Operating Officer, will review the strategic collaboration for Tumor Treating Fields in Greater China and address questions from the audience. The investor event will be held in conjunction with the BioCentury-BayHelix China Healthcare Summit 2018 and will begin at 2:30 p.m. China Time.
Novocure is an oncology company developing a profoundly different cancer treatment utilizing a proprietary therapy called Tumor Treating Fields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure’s commercialized product is approved for the treatment of adult patients with glioblastoma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and mesothelioma.
Zai Lab (NASDAQ: ZLAB) is a Shanghai-based innovative biopharmaceutical company focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. The Company’s experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates targeting the fast-growing segments of China’s pharmaceutical market and global unmet medical needs.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »